Format

Send to

Choose Destination
Curr Opin Pharmacol. 2018 Oct;42:1-6. doi: 10.1016/j.coph.2018.05.006. Epub 2018 May 31.

The antimalarial pipeline.

Author information

1
Medicines for Malaria Venture, 20 route de Pre-Bois, 1215 Geneva, Switzerland.
2
Medicines for Malaria Venture, 20 route de Pre-Bois, 1215 Geneva, Switzerland. Electronic address: wellst@mmv.org.

Abstract

Over the past decade, new high-throughput phenotypic assays with malaria parasites have been developed, and these were used to screen millions of compounds. This effort, as well as improving older chemical scaffolds and optimising compounds against both known and new drug targets has resulted in the discovery of exciting new pipeline drug candidates that are now being evaluated in a number of clinical trials. In addition, the pitfalls and opportunities from this experience has led to a better definition of the optimal target compound and product profiles for new antimalarials, including medicines that treat uncomplicated or severe malaria, provide chemoprevention, or stop disease transmission, covering all stages of the parasite. An important decision element is how to combine these new molecules with existing ones in today's dynamic resistance landscape.

PMID:
29860174
DOI:
10.1016/j.coph.2018.05.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center